We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Long-term Prophylaxis Against Aerosolized Marburg Virus in Nonhuman Primates With an Afucosylated Monoclonal Antibody.
- Authors
Abelson, Dafna; Barajas, Jennifer; Stuart, Lauren; Kim, Do; Marimuthu, Arumugapradeep; Hu, Chris; Yamamoto, Brent; Ailor, Eric; Whaley, Kevin J; Vu, Hong; Agans, Krystle N; Borisevich, Viktoriya; Deer, Daniel J; Dobias, Natalie S; Woolsey, Courtney; Prasad, Abhishek N; Peel, Jennifer E; Lawrence, William S; Cross, Robert W; Geisbert, Thomas W
- Abstract
Marburg virus (MARV) causes a hemorrhagic fever disease in human and nonhuman primates with high levels of morbidity and mortality. Concerns about weaponization of aerosolized MARV have spurred the development of nonhuman primate (NHP) models of aerosol exposure. To address the potential threat of aerosol exposure, a monoclonal antibody that binds MARV glycoprotein was tested, MR186YTE, for its efficacy as a prophylactic. MR186YTE was administered intramuscularly to NHPs at 15 or 5 mg/kg 1 month prior to MARV aerosol challenge. Seventy-five percent (3/4) of the 15 mg/kg dose group and 50% (2/4) of the 5 mg/kg dose group survived. Serum analyses showed that the NHP dosed with 15 mg/kg that succumbed to infection developed an antidrug antibody response and therefore had no detectable MR186YTE at the time of challenge. These results suggest that intramuscular dosing of mAbs may be a clinically useful prophylaxis for MARV aerosol exposure.
- Subjects
MARBURG virus; MONOCLONAL antibodies; HEMORRHAGIC fever; PRIMATES; BLOOD serum analysis
- Publication
Journal of Infectious Diseases, 2023, Vol 228, pS701
- ISSN
0022-1899
- Publication type
Article
- DOI
10.1093/infdis/jiad278